| Document |
Document Title |
|
WO/2021/069691A1 |
Disclosed herein is a method for covalent immobilization of molecular compounds on a substrate surface, comprising the steps: Providing a substrate surface; Treating the substrate surface with a plasma at atmospheric pressure, thereby ge...
|
|
WO/2021/062960A1 |
An application of an PEG interferon and a proto-oncogene product targeted inhibitor in synergistic treatment of renal carcinoma. Specifically, provided is use of a combination of active components, the combination of active components co...
|
|
WO/2021/062961A1 |
An application of PEG-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-inte...
|
|
WO/2021/055467A1 |
This disclosure relates generally to orally administrable nanoparticle for treating and preventing viral infection, specifically ZIKA and coronavirus infections. Methods for using the orally administrable nanoparticle are also provided f...
|
|
WO/2021/055083A1 |
In some examples, a CSS-MBs includes a solid magnetic core, a first shell material which surrounds the solid magnetic core and a second shell material which surrounds the first shell material. The first shell material may be a protective...
|
|
WO/2021/043865A1 |
The present invention relates to a "one-pot" method for preparing an aqueous solution of nanoparticles with amphiphilic block copolymers and comprising polypeptide units, the method comprising at least one step (E1), in an aqueous solven...
|
|
WO/2021/039884A1 |
Provided is a novel vesicle that is useful for introducing a functional molecule to a plant cell.　A cell membrane-permeable vesicle, which comprises a polyion complex vesicle and a cell-penetrating peptide presented at the surface ther...
|
|
WO/2021/016509A1 |
An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NPDPNANPNVDPNAN (amino acids 5-19 of SEQ ID NO:1) linked to the ...
|
|
WO/2021/014220A1 |
The present disclosure provides compositions and methods comprising platelets loaded with an agent. Agents loaded into platelets are generally protected from degradation and the subject is protected from toxicity, if any, from the agent....
|
|
WO/2021/011927A1 |
Methods and compositions for inhibiting complement are described.
|
|
WO/2021/006075A1 |
The purpose of the present invention is to provide a method for inducing a presynapse formation in human neurons.　According to the present invention, provided are: a method for inducing a presynapse formation in human neurons, the meth...
|
|
WO/2021/005857A1 |
Provided are: a novel anti-Aβ antibody capable of detecting an Aβ-related peptide; and a method and a kit for measuring an Aβ-related peptide in a biological sample by immunochemically using said novel anti-Aβ antibody. This monoclon...
|
|
WO/2020/262550A1 |
According to the present invention, a polymeric complex includes a protein and a block copolymer represented by formula (1).
|
|
WO/2020/252883A1 |
A synthesis method for thymosin Tα-1, comprising the following steps: 1) according to an Fmoc solid-phase synthesis method, coupling amino acids one by one to a solid-phase carrier, and synthesizing the 5-peptide resin of a side-chain p...
|
|
WO/2020/241617A1 |
The present invention addresses the problem of providing a method for judging inflammatory bowel disease that comprises a simple measurement procedure and correctly reflects clinical conditions.　The present invention pertains to "an an...
|
|
WO/2020/239983A1 |
The invention provides enzyme particles comprising an immobilized lipolytic enzyme, a hydrophobic polymer, an organic filter aid, and a water-soluble polyol selected from carbohydrates and sugar alcohols. The particles are suitable for e...
|
|
WO/2020/237134A1 |
Methods and compositions using artificial antigen presenting cells in immunotherapy. The artificial antigen presenting cells comprise substrate particles bound to endogenous MHC-peptide complexes obtained from one or more cells. Methods ...
|
|
WO/2020/236850A1 |
The present invention relates to immunotherapy, transplant therapy, therapy for rheumatic diseases, therapy for inflammatory diseases, and assessment of disease progression and immunotolerance. It provides devices that allow capturing an...
|
|
WO/2020/227814A1 |
Proteinaceous cellulose microparticles are provided. These microparticles comprise cellulose nanocrystals and one or more peptide, one or more protein, or a mixture thereof, wherein the nanocrystals and the peptide(s) and/or protein(s) a...
|
|
WO/2020/221937A1 |
The present invention relates to an immunogen for use in preventing or treating familial frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and/or amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) in patient...
|
|
WO/2020/202947A1 |
Provided is an affinity support having an improved target-protein-binding capacity. An immunoglobulin-binding protein containing at least one mutant immunoglobulin-binding domain; and an affinity support comprising a solid support having...
|
|
WO/2020/202987A1 |
The present invention provides: a biocompatible material which has improved biocompatibility by having a peptide adsorb thereon, said peptide having high adhesion to resins and being not easily separated from the surfaces of resins; and ...
|
|
WO/2020/205808A1 |
Combination therapties for the treatment of cancer comprising an immunostimulatory fusion molecules that include an immune cell targeting moiety and a cytokine molecule; and an immune cell loaded with protein nanogels that include a reve...
|
|
WO/2020/201568A1 |
The present invention relates to a kit-of-parts comprising and a composition comprising a polyplex comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (...
|
|
WO/2020/193486A1 |
The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the...
|
|
WO/2020/198644A1 |
The present disclosure is directed to physical mixtures of diblock copolypeptide hydrogel (DCH) systems. These systems exhibit mechanical strength and stiffness that are synergistically increased over the individual component DCHs, to gr...
|
|
WO/2020/195514A1 |
A purpose of the present invention is to provide a method for efficiently supporting a thiol group-including compound on an insoluble substrate. This method for supporting a thiol group-including compound on an insoluble substrate is cha...
|
|
WO/2020/193487A1 |
The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold and at least a first peptide n-mer of the...
|
|
WO/2020/189766A1 |
The purpose of the present invention is to provide a polypeptide-modified liposome which has excellent antibody binding capacity.　In each immunoglobulin binding domain (sequence number 1-4) configuring a protein A, at least 3 amino aci...
|
|
WO/2020/047185A9 |
The present invention includes a composition and method of allosterically potentiating the activity of neurolysin comprising contacting the neurolysin with an amount of a histidine-containing dipeptide that is an allosteric that increase...
|
|
WO/2020/181393A1 |
Various embodiments are described herein for the fabrication enzyme degradable hydrogels useful as payload delivery systems. More particularly, embodiments disclosed herein relate to enzyme-degradable hydrogel systems comprising a crossl...
|
|
WO/2020/172218A1 |
The subject invention provides a composition comprising an enomomer which comprises a) a carrier molecule, and b) at least one aptamer, wherein the carrier molecule is an antibody, an antigen-binding moiety, a serum protein, an intracell...
|
|
WO/2020/172590A1 |
The present invention relates generally to methods of generating a biomimetic cell wall (BCW) on a target surface, compositions comprising the BCW, and methods of use of the compositions, including biomedical applications of the BCW coat...
|
|
WO/2020/158691A1 |
An objective of the present invention is to provide a variant of a hepatocyte growth factor or active fragment thereof capable of lowering liver tropism and selectively expressing bioactivity in target disease tissue other than liver tis...
|
|
WO/2020/158690A1 |
The purpose of the present invention is to provide a polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof wherein the effect of extending in vivo half life period of polyethylene glycol modificati...
|
|
WO/2020/158835A1 |
The problem addressed by the present invention is to provide a reagent kit, a measurement kit, and a measurement method for measurement of serum amyloid A that promote dissociation of serum amyloid A from HDL and make it possible to meas...
|
|
WO/2020/153253A1 |
Provided are porous zirconia particles having high specificity for immobilizing a specific protein. The porous zirconia particles are used for immobilizing protein. In a pore size distribution measured by a BET method, the fine pore diam...
|
|
WO/2020/125743A1 |
Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an imm...
|
|
WO/2020/114358A1 |
Provided are a specifically binding CD19 antibody or an antigen binding fragment thereof, wherein the antibody binds to a CD19 protein having 3.5μg/mL or lower IC50, and the uses the antibody or the antigen binding fragment thereof in p...
|
|
WO/2020/111028A1 |
A method in which gold particles are coated with protein, the method being characterized by using either of the following buffering solutions. 1) A buffering solution that has a final salt concentration, excluding MgCl2 and DTT, of great...
|
|
WO/2020/110982A1 |
The inventors of the present invention found that patients in an at-risk mental state (ARMS) have significantly increased biopyrrin and cortisol, and significantly decreased immunoglobulin κ free light chain (κFLC) and immunoglobulin Î...
|
|
WO/2020/109833A1 |
The present invention relates to a method for immobilizing a peptide, in particular a CD31-mimetic peptide on a substrate surface, in particular a stent surface, allowing a strong anchoring of said peptide onto a polydopamine polymer fun...
|
|
WO/2020/111029A1 |
A method in which a solution that includes an amphipathic molecule and protein is used to coat gold particles.
|
|
WO/2020/081716A3 |
The present invention includes a polypeptide for use in a three dimensional (3D) culture system for the growth of cells comprising one or more repeats of a sequence n1-(X1X2GXP)-n2 (SEQ ID NO: 8), wherein X1 and X2 are any amino acids ex...
|
|
WO/2020/105700A1 |
The present invention provides a technique for improving the sensitivity in an immunological measurement of tau protein. More specifically, the present invention provides: an antibody conjugate comprising at least two anti-tau protein an...
|
|
WO/2020/104440A1 |
The disclosed technology relates to a method of immobilising a protein on a substrate. The disclosed technology further relates to the substrate comprising the immobilised protein, the use of the substrate in a wound dressing, and the us...
|
|
WO/2020/102609A1 |
The invention provides compositions and methods for the cytoplasmic delivery of antibodies and other proteins. Specifically, provided herein are compositions having an anionic polypeptide and a cationic transfection agent for facilitatin...
|
|
WO/2020/095985A1 |
Provided is a method for producing a peptide-nucleic acid complex that contains a peptide and nucleic acid encoding the peptide. The method comprises a step of preparing a nucleic acid containing a first coding sequence that encodes a pe...
|
|
WO/2020/096020A1 |
The purpose of the present invention is to provide a method for producing a peptide that interacts with a lipid bilayer, and a lipid-bilayer-penetrating peptide obtained through the method. Provided is a lipid-bilayer-penetrating peptide...
|
|
WO/2020/027585A3 |
The present invention relates to a polypeptide delivery composition, which comprises porous artificial chaperone particles having an average pore diameter of 1-100 nm, so as to make polypeptides become stapled, thereby fixedly changing t...
|
